Dabo Medical announced that on May 19, 2026, the company decided to use 130 million to 260 million yuan of its own capital to repurchase shares for equity incentives. The repurchase price will not exceed 50 yuan/share, and the implementation period will be 12 months. Due to the implementation of the 2025 equity distribution, the maximum repurchase price was adjusted to 49.41 yuan/share from July 7. As of July 31, the company had repurchased 4.493,400 shares, accounting for 1.0853% of the total share capital. The highest transaction price was 43 yuan/share, the lowest transaction price was 39.62 yuan/share, and the total transaction amount was 185 million yuan. In the future, repurchases will continue to be implemented and disclosed in accordance with regulations.

Dabo Medical announced that on May 19, 2026, the company decided to use 130 million to 260 million yuan of its own capital to repurchase shares for equity incentives. The repurchase price will not exceed 50 yuan/share, and the implementation period will be 12 months. Due to the implementation of the 2025 equity distribution, the maximum repurchase price was adjusted to 49.41 yuan/share from July 7. As of July 31, the company had repurchased 4.493,400 shares, accounting for 1.0853% of the total share capital. The highest transaction price was 43 yuan/share, the lowest transaction price was 39.62 yuan/share, and the total transaction amount was 185 million yuan. In the future, repurchases will continue to be implemented and disclosed in accordance with regulations.